NCT04979923

Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 81 (estimated)
• Sponsor: Sheikh Zayed Medical College · Other Government
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Conditions

• COVID-19 Acute Respiratory Distress Syndrome

Interventions

Type	Name	Description
DRUG	Lidocaine	Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Timeline

• Start date: 2021-07-01
• Primary completion: 2021-07-31
• Completion: 2021-08-01
• First posted: 2021-07-28
• Last updated: 2021-07-28

Locations

1 site across 1 country: Pakistan